Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.
Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model.
复制标题
DOI：
10.1371/journal.pone.0013460
复制
发表时间：
2010-10-18
期刊：
影响因子：
3.7
通讯作者：
Kendall MA
中科院分区：
文献类型：
--
作者：
Corbett HJ;Fernando GJ;Chen X;Frazer IH;Kendall MA
常规使用的疫苗需要更好的输送系统，以提高疫苗接种率。许多疫苗含有明矾或明矾佐剂。在这里，我们研究了一种新型干涂层致密包装微投影阵列皮肤贴片(Nanopatch™)，作为肌肉注射的替代递送系统，用于递送通常用作宫颈癌预防疫苗的明矾佐剂型人乳头瘤病毒疫苗(GADARASIL®)。干包被疫苗材料(Gardasil®)的微投影阵列在5分钟内释放到C57BL/6小鼠耳部皮肤。为评价疫苗的免疫原性，在0天和14天分别给予相应于HPV16组分的剂量为(0.43±0.084)ng~(30 0±12 0)ng(平均值±SD)的疫苗。微投影阵列皮内注射的剂量为5 5±6.0 ng，足以在接种后2 8d产生最大的病毒中和血清抗体应答。中和抗体滴度在接种后持续到16周，对于相同剂量的疫苗，在这个时间点，皮内贴剂注射的效价略高于针头和注射器肌肉注射的效价。使用干式微凸起阵列(Nanopatch™)有可能克服目前通过针头和注射器输送的常见疫苗需要疫苗冷链，并降低针头刺伤的风险和由于害怕针头而避免疫苗接种，特别是在儿童中。
Better delivery systems are needed for routinely used vaccines, to improve vaccine uptake. Many vaccines contain alum or alum based adjuvants. Here we investigate a novel dry-coated densely-packed micro-projection array skin patch (Nanopatch™) as an alternate delivery system to intramuscular injection for delivering an alum adjuvanted human papillomavirus (HPV) vaccine (Gardasil®) commonly used as a prophylactic vaccine against cervical cancer. Micro-projection arrays dry-coated with vaccine material (Gardasil®) delivered to C57BL/6 mouse ear skin released vaccine within 5 minutes. To assess vaccine immunogenicity, doses of corresponding to HPV-16 component of the vaccine between 0.43±0.084 ng and 300±120 ng (mean ± SD) were administered to mice at day 0 and day 14. A dose of 55±6.0 ng delivered intracutaneously by micro-projection array was sufficient to produce a maximal virus neutralizing serum antibody response at day 28 post vaccination. Neutralizing antibody titres were sustained out to 16 weeks post vaccination, and, for comparable doses of vaccine, somewhat higher titres were observed with intracutaneous patch delivery than with intramuscular delivery with the needle and syringe at this time point. Use of dry micro-projection arrays (Nanopatch™) has the potential to overcome the need for a vaccine cold chain for common vaccines currently delivered by needle and syringe, and to reduce risk of needle-stick injury and vaccine avoidance due to the fear of the needle especially among children.
登录
查看更多内容
影响因子：
3.4
作者：
BAKER, TS;NEWCOMB, WW;BROWN, JC
通讯作者：
BROWN, JC
DOI：
10.4161/hv.8485
发表时间：
2009-07-01
期刊：
HUMAN VACCINES
影响因子：
--
作者：
Le Tallec, David;Doucet, Diane;Deschamps, Marguerite
通讯作者：
Deschamps, Marguerite
影响因子：
3.7
作者：
Fernando GJ;Chen X;Prow TW;Crichton ML;Fairmaid EJ;Roberts MS;Frazer IH;Brown LE;Kendall MA
通讯作者：
Kendall MA
影响因子：
3.7
作者：
Maa, YF;Shu, C;Chen, DX
通讯作者：
Chen, DX
影响因子：
120.7
作者：
Dunne, Eileen F.;Unger, Elizabeth R.;Markowitz, Lauri E.
通讯作者：
Markowitz, Lauri E.